帕姆普里丁对患有多发性硬化症 (MS) 的患者认知的影响:系统性审查和元分析
Abdorreza Naser Moghadasi1, Narges Ebrahimi2, Sara Bagherieh2
1Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Caspian journal of internal medicine
|August 11, 2025
概括
芬普里丁显著改善了多发性硬化症 (MS) 患者的认知功能,解决了残疾的认知障碍. 这一系统性审查和元分析证实了fampridine的存在.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知障碍 (CI) 是多发性硬化症 (MS) 患者的重大致残并发症.
- 芬普里丁用于增强MS患者的行走能力,并显示出潜在的认知改善,尽管结果不一致.
- 显而易见的是,需要对Fampridine在MS中的认知影响进行全面分析.
研究的目的:
- 进行系统审查和元分析.
- 研究fampridine在改善多发性硬化症 (MS) 患者的认知功能方面的疗效.
主要方法:
- 在主要数据库 (PubMed,EMBASE,Scopus,Web of Science,Google Scholar) 和灰色文献中进行了全面的文献搜索.
- 数据提取包括参与者的人口统计,疾病特征,治疗细节和认知测试得分.
- 2013年至2021年间发表的15项研究被纳入了元分析.
主要成果:
- 分析显示,普利丁对认知功能有显著的积极影响.
- 符号数字模式测试 (SDMT) 的标准化平均差异 (SMD) 为0.45 (95% CI:0.06-0.84).
- 步调听力序列加法测试 (PASAT) 的SMD为0.25 (95%CI:0.13-0.37),表明认知表现有所改善.
结论:
- 范普里丁在减轻MS患者认知障碍方面发挥着重要作用.
- 这些发现支持使用fampridine作为治疗多发性硬化症认知缺陷的治疗选择.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
01:24Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
01:26Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668